Key Drivers
- Profitability Strength
- Cash Conversion
- Leverage Risk
AIAI Summary
GILD should now be viewed less as a mature HIV cash cow and more as a self-funding reinvestment story, with strong cash flow, rising liquidity, and new growth options in HIV prevention, oncology, and liver/infectious disease—but the stock's rerating depends on these assets scaling fast enough to offset leverage and execution risk in the core franchise.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Profitability Strength
- •Cash Conversion
- •Leverage Risk
GILD combines strong profitability, robust cash generation, and sustainable dividends, but its attractive valuation is offset by meaningful leverage and intangible-asset risk.
Price Behavior
Key Price Behavior Insights:
- •Strong rebound
- •Range breakout
- •Volatile recovery
GILD is leaning bullish over the last month after rebounding from $120.69 and closing at the top of its range, but it needs to hold above $127/$124-$125 and clear $131.27 to confirm follow-through.
Sharp rebound from $120.69 after a choppy pullback
Sentiment & News
Key News Insights:
- •HIV Growth
- •Regulatory Wins
- •Oncology Split
Gilead's outlook improved on stronger HIV momentum and key regulatory wins, though oncology remains mixed after a lung-cancer study setback.
The news is modestly positive for Gilead, supporting sentiment on HIV-led growth while keeping oncology execution as the main risk
Similar Companies in Healthcare
Other companies in the same sector with AI ratings